Radiation Oncology Clinical Research Seminar to be Held at the University of Florida

Publication
Article
OncologyONCOLOGY Vol 13 No 11
Volume 13
Issue 11

A three-day interdisciplinary cancer conference will be held March 2 through 4, 2000, at the Best Western Gateway Grand in Gainesville, Florida. The seminar will emphasize the latest advances in radiation therapy techniques and results. It will include refresher courses by senior faculty, panel discussions, and new departmental research results. Visiting Professor will be Professeur Jean-Pierre Gerard, Service de Radiotherapie-Oncologie, Hôpitaux de Lyon, France. Other presentations will be made by clinicians from the University of Florida Department of Radiation Oncology.

A three-day interdisciplinary cancer conference will be held March 2 through 4, 2000, at the Best Western Gateway Grand in Gainesville, Florida. The seminar will emphasize the latest advances in radiation therapy techniques and results. It will include refresher courses by senior faculty, panel discussions, and new departmental research results. Visiting Professor will be Professeur Jean-Pierre Gerard, Service de Radiotherapie-Oncologie, Hôpitaux de Lyon, France. Other presentations will be made by clinicians from the University of Florida Department of Radiation Oncology.

Concurrent meetings will be held for radiation therapy physicists on March 2 and 3, for radiation therapists on March 3 and 4, and for radiation oncology nurses on March 3 and 4. For further information, contact:
William M. Mendenhall, MD, 2000 Seminar Coordinator, Department of Radiation Oncology, University of Florida , Health Science Center, P. O. Box 100385, Gainesville, FL 100385, Phone: (352) 395-0287, Fax: (352) 395-0759, e-mail: mendewil@shands.ufl.edu

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content